StreetInsider.com News Articles

Elutia regains compliance with NASDAQ listing requirements

Wed, 04 Mar 2026 08:01:40 -0500

Elutia Inc. (NASDAQ: ELUT) announced it has received notice from Nasdaq that the company has regained compliance with minimum bid price and market value requirements for continued listing. The biotechnology company, which develops drug-eluting biomatrix technologies, is now in full compliance with all Nasdaq continued listing requirements.

Nasdaq advised that the compliance matters are closed, and Elutia's Class A common stock will continue trading on the Nasdaq Capital Market under the symbol "ELUT."

The company had previously been subject to Nasdaq Listing Rules 5550(a)(2) regarding minimum bid price and 5550(b)(2) concerning minimum market value of listed securities. Companies typically receive deficiency notices

Elutia regains compliance with NASDAQ listing requirements

Wed, 04 Mar 2026 08:01:40 -0500

Nasdaq advised that the compliance matters are closed, and Elutia's Class A common stock will continue trading on the Nasdaq Capital Market under the symbol "ELUT."

Form 8-K ELUTIA INC. For: Mar 04

Wed, 04 Mar 2026 08:01:00 -0500

si-local-file:///var/storage/secattach/20260304/26107516.html

Form 8-K ELUTIA INC. For: Mar 04

Wed, 04 Mar 2026 08:01:00 -0500

si-local-file:///var/storage/secattach/20260304/26107516.html

Elutia Regains Compliance with Nasdaq Listing Requirements

Wed, 04 Mar 2026 08:00:00 -0500

GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the Company is now in full compliance with all Nasdaq continued listing requirements, and Nasdaq has advised that these matters are now closed. The Company’s Class A common stock

Elutia Regains Compliance with Nasdaq Listing Requirements

Wed, 04 Mar 2026 08:00:00 -0500

Elutia Regains Compliance with Nasdaq Listing Requirements

Wed, 04 Mar 2026 08:00:00 -0500

Elutia Regains Compliance with Nasdaq Listing Requirements

Wed, 04 Mar 2026 08:00:00 -0500

Elutia names Pete Ligotti as chief commercial officer

Mon, 02 Mar 2026 08:01:07 -0500

Elutia Inc. (NASDAQ: ELUT) appointed Pete Ligotti as chief commercial officer to lead the commercialization of NXT-41x, the company's antibiotic-eluting biomatrix product for plastic and reconstructive surgery.

NXT-41x targets the breast reconstruction market, where over 162,000 procedures are performed annually in the United States. The company states that biological surgical mesh is used in over 80% of these cases, yet infection rates of 15% to 20% persist. Elutia estimates the biologics for breast reconstruction market represents a $1.5 billion opportunity in the U.S.

Ligotti brings 20 years of experience in surgical markets. At Integra LifeSciences, he built the plastic and reconstructive surgery

Elutia names Pete Ligotti as chief commercial officer

Mon, 02 Mar 2026 08:01:07 -0500

Ligotti brings 20 years of experience in surgical markets. At Integra LifeSciences, he built the plastic and reconstructive surgery

Elutia names Pete Ligotti as chief commercial officer

Mon, 02 Mar 2026 08:01:07 -0500

Ligotti brings 20 years of experience in surgical markets. At Integra LifeSciences, he built the plastic and reconstructive surgery

Elutia names Pete Ligotti as chief commercial officer

Mon, 02 Mar 2026 08:01:07 -0500

Ligotti brings 20 years of experience in surgical markets. At Integra LifeSciences, he built the plastic and reconstructive surgery

Elutia names Pete Ligotti as chief commercial officer

Mon, 02 Mar 2026 08:01:07 -0500

Ligotti brings 20 years of experience in surgical markets. At Integra LifeSciences, he built the plastic and reconstructive surgery

Elutia names Pete Ligotti as chief commercial officer

Mon, 02 Mar 2026 08:01:07 -0500

Ligotti brings 20 years of experience in surgical markets. At Integra LifeSciences, he built the plastic and reconstructive surgery

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market